Caris Life Sciences, Inc. CAI
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. 10-K, Item 1
- Employees
- 1,846
- Headquarters
- Irving, TX
- Next results
- around Jan 11, 2027
CAI among Health care peers
Six ratios from the latest 10-K. Each corner is the share of 154 peers the company is above, not a score.
What changed
Nothing new in the latest 10-K.
Each row opens the detail with the quote and the filing. A row is a change worth reading, not a verdict.
Accounting checks
9 checks on the latest 10-K. Checks, not verdicts.
0facts worth reading about all 9 checks found nothing to note
-
Receivables +27.1% ($88.2M to $112.1M) vs revenue +97.0% ($412.3M to $812.0M), -69.9 pts apart
-
Cash from operations $83.2M vs net income −$68.1M (FY ending Dec 31, 2025)
-
Auditor names not available for both 10-Ks; no 8-K item 4.01
6 more checks with nothing to note
-
No statement of substantial doubt about going concern
-
No 8-K item 4.02 in the last 2 years
-
No NT 10-K or NT 10-Q in the last 2 years
-
No sentence in the 10-K concludes that controls were not effective because of a material weakness
-
No 8-K item 2.06 in the last 2 years
-
No 8-K item 1.03 in the last 2 years
In their words
No new paragraphs in Risk Factors
No new paragraphs in Risk Factors, or fewer than two 10-Ks to compare.
Financial performance
Last 3 fiscal years · 10-K XBRL
| Metric | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | $306.1M | $412.3M | $812.0M |
| Net income | −$341.4M | −$281.9M | −$68.1M |
| Operating cash flow | −$276.1M | −$245.2M | $83.2M |
| Free cash flow | −$298.4M | −$253.6M | $66.9M |
Revenue, FY2023 to FY2025
Ten fiscal years, each from its own 10-K · XBRL · USD
$812.0M ▲ 97.0% in FY2025−$68.1M in FY2025$66.9M in FY2025
Recent filings
2 filings in the last 30 days · SEC EDGAR
-
8-KNov 4, 2026Quarterly results 8-K item 2.02
-
10-QNov 4, 2026Quarterly report (10-Q) period ended Sep 30, 2026
About the company
Caris Life Sciences, Inc., Irving, TX · from the 10-K filed Mar 3, 2026
We are a leading, patient-centric, next-generation AI TechBio company and precision medicine pioneer. We develop and commercialize innovative solutions to transform healthcare through the use of comprehensive molecular information and artificial intelligence/machine learning algorithms at scale. Our entire portfolio of precision medicine solutions is designed to benefit patients, with an initial focus on oncology, and serves the clinical, academic, and biopharma markets.
- Headquarters
- Irving, TX
- Country
- United States
- Reports in
- USD
- Listed on
- Nasdaq
- Fiscal year ends
- December 31
- Last results
- Nov 4, 2026
- Incorporated in
- TX
Employees, at the top of the page: "As of December 31, 2025, we had 1,846 employees" (10-K). Address and exchange: SEC's company file.
Email alerts
Sources
Numbers from the XBRL of the 10-Ks; filings from SEC EDGAR.
Work with it: Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/CAI/export.csv") into a cell.